Published online Oct 10, 2016. doi: 10.5306/wjco.v7.i5.337
Peer-review started: June 28, 2016
First decision: August 5, 2016
Revised: September 2, 2016
Accepted: September 21, 2016
Article in press: September 23, 2016
Published online: October 10, 2016
Processing time: 103 Days and 12.3 Hours
Transanal total mesorectal excision (TaTME) is a new and promising approach for the treatment of rectal cancer. Whilst the experience is still limited, there are growing evidences that this approach might overcome the limits of standard low anterior resection. TaTME might help to decrease the conversion rate especially in difficult patients, and to improve the pathological results, while preserving the urogenital function. Evaluation of data from large registries and randomized studies should help to draw firmer conclusions. Beyond these technical considerations, the next challenge seems to be clearly the safe introduction of this approach, motivating the development of dedicated courses.
Core tip: The experience and evidences regarding the use of transanal total mesorectal excision is still scarce but promising. Preliminary data showed excellent results, without sacrificing the pathological and oncological outcomes. Whilst still in its infancy, further investigations should be encouraged. Data from large registries and randomized trials are awaited before to draw definitive conclusions.